natgillin/translations-raw huggingface dataset:
PFS was defined as the time from randomisation to the earliest date of disease progression or death from any cause, or to the date of censor.
Preživetje brez napredovanja (PFS) je bilo opredeljeno kot čas od randomizacije do najzgodnejšega datuma napredovanja bolezni ali smrti zaradi kakšnega koli vzroka ali pa do datuma krnjenja.
PFS was significantly longer in patients receiving Stivarga plus BSC (hazard ratio: 0.494, p<0.000001, see Table 6).
Preživetje brez napredovanja bolezni je bilo pomembno daljše pri bolnikih, ki so prejemali zdravilo Stivarga in najboljšo podporno oskrbo (razmerje ogroženosti: 0,494; p < 0,000001, glejte preglednico 6).
PFS was statistically significantly improved in patients receiving Cyramza plus docetaxel compared with those receiving placebo plus docetaxel (HR 0.762; 95% CI: 0.677 to 0.859; p<0.001).
Preživetje brez napredovanja bolezni se je statistično pomembno izboljšalo pri bolnikih, ki so prejemali zdravilo Cyramza in docetaksel, v primerjavi z bolniki, ki so prejemali placebo in docetaksel (RT: 0,762; 95 % IZ: 0,677 do 0,859; p < 0,001).
PFS, mediana [95% CI]b (weeks) Sequential HR [95% CI]e Sequential log-rank test, p-valuee
PFS, medianaa [95 % IZ]b (tedni)
PFS2  (months) ¤
PFS2  (meseci) ¤
PFS2e  (months)
PFS2e  (meseci)
PFS: progression-free survival; EFS: event-free survival; OS: overall survival; TNLT: time to next anti-lymphoma treatment; TNCT: Time to next chemotherapy treatment; ORR: overall response rate; NR: not reached at time of clinical cut-off, OR: odds ratio.
PFS: preživetje brez napredovanja bolezni; EFS: preživetje brez dogodkov; OS: celokupno preživetje; TNLT: čas do naslednjega zdravljenja limfoma; TNCT: čas do naslednje kemoterapije; ORR: celokupni odgovor; NR: ni doseženo ob času kliničnega zaključka zbiranja podatkov (not reached); RO: razmerje obetov; CR: popolni odgovor; CRu: nepotrjen popolni odgovor.
PFS: progression-free survival; EFS: event-free survival; OS: overall survival; TNLT: time to next anti-lymphoma treatment; TNCT: time to next chemotherapy treatment; ORR: overall response rate; NR: not reached at time of clinical cut-off, OR: odds ratio.
Vrednosti zunaj oklepajev ustrezajo mediani časa opazovanja 48 mesecev (posodobljena analiza). a zdravljenja limfoma; TNCT: čas do naslednje kemoterapije; ORR: celokupni odgovor; NR: ni doseženo ob času kliničnega zaključka zbiranja podatkov (not reached); RO: razmerje obetov; CR: popolni odgovor; CRu: nepotrjen popolni odgovor
PFS:Progression-free survival; ORR:Objective response rate; OR:Objective response; CBR:Clinical benefit rate; CB:Clinical benefit; OS:Overall survival; K-M:Kaplan-Meier; CI:Confidence interval; AI:Aromatase inhibitor; AE:Anti-estrogen.
PFS: preživetje brez napredovanja bolezni; ORR: objektivni delež odziva; OR: objektivni odziv; CBR: delež klinične dobrobiti; CB:klinična korist; OS: celotno preživetje; K-M:Kaplan-Meier; IZ: interval zaupanja; AI: zaviralec aromataze; AE: antiestrogen.
PFTiSmeT(iMmoe (hMs)onths)
ilit ab 0 rob 0
PGA of Cleared (0)
PGA čisto (0)
PGA of cleared (0) or minimal (1)
PGA čisto (0) ali minimalno (1)
PGA of cleared or minimal N (%)
PGA pri bolnikih brez sprememb ali z minimalnimi spremembami N (%)
PGA:
14
PGA: Clear/minimalc
PGA: čisto/minimalnoc
PGAb of cleared or minimal N (%)
PGAb pri bolnikih brez sprememb ali z minimalnimi spremembami N (%)
Ph+ acute lymphoblastic leukaemia (ALL), a type of cancer in which lymphocytes (another type of white blood cell) multiply too quickly.
Ph+ akutne limfoblastne levkemije (ALL), vrste raka, pri kateri se limfociti (druga vrsta belih krvnih celic) prehitro množijo.
Ph+ CP
88,8)
Ph+ CP CML
Ph+ KML v
Ph+ means that some of the patient’s genes have rearranged themselves to form a special chromosome called the Philadelphia chromosome that leads to the development of leukaemia.
Ph+ pomeni, da so se nekateri bolnikovi geni prerazporedili tako, da tvorijo poseben kromosom, imenovan kromosom Philadelphia, ki povzroča razvoj levkemije.
Ph+ means that some of the patient’s genes have rearranged themselves to form a special chromosome called the Philadelphia chromosome which produces an enzyme, Bcr-Abl kinase, that leads to the development of leukaemia.
Ph+ pomeni, da so se geni nekaterih bolnikov prerazporedili tako, da tvorijo poseben kromosom, ki se imenuje kromosom Philadelphia.
PHACE syndrome
Sindrom PHACE
phaeochromocytoma (a tumour of the adrenal gland);
feokromocitom (tumor nadledvične žleze);
phaeochromocytoma (a tumour of the adrenal gland);
feokromocitomom (tumorjem nadledvične žleze);
phaeochromocytoma (a tumour of the adrenal gland); a history of neuroleptic malignant syndrome (a dangerous nervous system disorder usually caused by antipsychotic medicines) or rhabdomyolysis (breakdown of muscle fibres).
feokromocitom (tumor nadledvične žleze); anamnezo nevroleptičnega malignega sindroma (nevarne bolezni živčnega sistema, ki jo običajno povzročijo antipsihotična zdravila) ali rabdomiolize (razgradnje mišičnega tkiva).
phaeochromocytoma (a tumour of the adrenal gland); a history of neuroleptic malignant syndrome (a dangerous nervous system disorder usually caused by antipsychotic medicines) or rhabdomyolysis (breakdown of muscle fibres).
feokromocitomom (tumorjem nadledvične žleze), ki so imeli v preteklosti nevroleptični maligni sindrom (nevarno obolenje živčnega sistema, ki ga običajno povzročijo antipsihotična zdravila) ali rabdomiolizo (razgradnjo mišičnih vlaken).
Phamacovigilance system
Sistem farmakovigilance
Phantom limb pain
fantomska bolečina v okončinah
Pharma Docetaxel TEVA
(steklo);vehikel:
Pharma- ceutical Form
Farmace vtska oblika
Pharma- ceutical Form
Farmacevtska oblika
Pharma-Cos .Limited Tel: +356 21441 870
Pharma-Cos Limited Tel: +356 21441 870
PHARMAC EUTIC AL PARTIC ULARS
FARMACEVTSKI PODATKI
Pharmaceu- tical Form
Farmacevtska oblika
Pharmaceuti cal form
Farmacevtsk a oblika
Pharmaceuti cal form
Farmacevtska oblika
Pharmaceutical
Farmacevtsk a oblika
Pharmaceutical
Farmacevtska
Pharmaceutical
Farmacevtska oblika tableta
Pharmaceutical Form
(PVC/PCTFE/Alu)
Pharmaceutical form
EU/2/13/153/241
Pharmaceutical Form
Farmacevt ska oblika
Pharmaceutical Form
Farmacevtsk a oblika
Pharmaceutical form
Farmacevtska
Pharmaceutical form
Farmacevtska Ciljna
Pharmaceutical Form
Farmacevtske oblike
Pharmaceutical Form
Farmacvtska
Pharmaceutical Form
Farnacevtska oblika
PHARMACEUTICAL FORM
Halucinacije
Pharmaceutical Form
i.e./0,6
Pharmaceutical form
ka oblika
PHARMACEUTICAL FORM
LYFJAFORM
PHARMACEUTICAL FORM
Organski sistem
PHARMACEUTICAL FORM
Vrsta ovojnine in vsebina
PHARMACEUTICAL FORM AND CONTENTS
FARMACEVTSKA OBLIKA IN SESTAVA
PHARMACEUTICAL FORM AND CONTENTS
FARMACEVTSKA OBLIKA IN VSEBNOST
PHARMACEUTICAL FORM AND CONTENTS
KLINIČNI PODATKI
PHARMACEUTICAL FORM AND CONTENTS
LYFJAFORM OG INNIHALD
PHARMACEUTICAL FORM AND CONTENTS
NAVODILA ZA UPORABO
PHARMACEUTICAL FORM AND CONTENTS
OZNAČEVANJE IN NAVODILO ZA UPORABO
PHARMACEUTICAL FORM AND CONTENTS
PODATKI NA ZUNANJI OVOJNINI
PHARMACEUTICAL FORM AND CONTENTS
ŠTEVILKA SERIJE
PHARMACEUTICAL FORM Concentrate for solution for infusion Clear and colourless solution.
FARMACEVTSKA OBLIKA koncentrat za raztopino za infundiranje bistra in brezbarvna raztopina
PHARMACEUTICAL FORM Concentrate for solution for infusion.
FARMACEVTSKA OBLIKA koncentrat za raztopino za infundiranje.
PHARMACEUTICAL FORM Film-coated tablet Marixino 10 mg film-coated tablets
FARMACEVTSKA OBLIKA filmsko obložena tableta Marixino 10 mg filmsko obložene tablete
PHARMACEUTICAL FORM Inhalation powder.
FARMACEVTSKA OBLIKA
PHARMACEUTICAL FORM Powder for solution for injection.
FARMACEVTSKA OBLIKA
PHARMACEUTICAL FORM Prolonged-release tablet MIRAPEXIN 0.26 mg prolonged-release tablets
FARMACEVTSKA OBLIKA tableta s podaljšanim sproščanjem MIRAPEXIN 0,26 mg tablete s podaljšanim sproščanjem
PHARMACEUTICAL FORM Solution for injection in a cartridge.
FARMACEVTSKA OBLIKA Raztopina za injiciranje v vložku.
PHARMACEUTICAL FORM Solution for injection in cartridge.
FARMACEVTSKA OBLIKA
PHARMACEUTICAL FORM Solution for injection or infusion Clear, colourless solution
FARMACEVTSKA OBLIKA raztopina za injiciranje ali infundiranje bistra, brezbarvna raztopina.
PHARMACEUTICAL FORM Solution for injection or infusion Clear, colourless solution.
FARMACEVTSKA OBLIKA raztopina za injiciranje ali infundiranje Bistra, brezbarvna raztopina.
PHARMACEUTICAL FORM Solution for injection or infusion in a vial.
FARMACEVTSKA OBLIKA Raztopina za injiciranje ali infundiranje v viali.
PHARMACEUTICAL FORM Solution for injection.
FARMACEVTSKA OBLIKA
PHARMACEUTICAL FORM Solution for injection. (Injection).
FARMACEVTSKA OBLIKA Raztopina za injiciranje v vložku.
Pharmaceutical Form Suspension for
Farmacevtska
Pharmaceutical Forms
Farmacevtska oblika
Pharmaceutical Forms
Farmacevtske oblike
PHARMACEUTICAL PARTICULARS
(20,9-51,5)
PHARMACEUTICAL PARTICULARS
FARMACEVTSKE LASTNOSTI
PHARMACEUTICAL PARTICULARS
FARMACEVTSKEI PODATKI
PHARMACEUTICAL PARTICULARS
LYFJAGERÐARFRÆÐILEGAR UPPLÝSINGAR
PHARMACEUTICAL PARTICULARS
Organski sistem
PHARMACEUTICAL PARTICULARS
Pediatrični bolniki
Pharmaceutical Target species
Farmacevtska oblika
Pharmachemie B.V.
Pharmachemie B.V. Swensweg 5,
Pharmacist educational material
Izobraževalno gradivo za farmacevte
Pharmacists - a detailed letter explaining the switch between the two formulations
farmacevti – dopis s podrobnim opisom prehajanja med obema formulacijama,
Pharmacist’s telephone:
Telefon farmacevta:
PHARMACO LOGICAL PROPERTIES
FARMAKOLOŠKE LASTNOSTI
Pharmaco- logically active substance
Farmakološko aktivna snov
Pharmaco- logically active substance
Farmakološko aktivna snov(i)
Pharmaco-therapeutic group:
Farmakoterapevtska skupina:
Pharmaco-therapeutic group: antiobesity preparations, excl. diet products, peripherally acting antiobesity products, ATC code A08AB01.
Farmakoterapevtska skupina: zdravila za zdravljenje debelosti brez proizvodov za dieto, periferno delojoča zdravila za zdravljenje debelosti, oznaka ATC: A08AB01
Pharmaco-therapeutic group: antivirals for systemic use, antivirals for treatment of HIV infections, combinations, ATC code: J05AR10
Farmakoterapevtska skupina: protivirusne učinkovine za sistemsko uporabo, protivirusne učinkovine za zdravljenje okužb s HIV, kombinacije, oznaka ATC: J05AR10
Pharmaco-therapeutic group: ATC Code: A10A D04.
Farmakoterapevtska skupina:
Pharmaco-therapeutic group: Bacterial and viral vaccines combined, ATC code: J07CA09
Farmakoterapevtska skupina: Kombinacija bakterijskih in virusnih cepiv, oznaka ATC: J07CA09
Pharmaco-therapeutic group: Intermediate acting human insulin analogue.
Farmakoterapevtska skupina: Analog humanega insulina s srednje dolgim delovanjem.
Pharmaco-therapeutic group: Local haemostatics, ATC code: B02BC30
Farmakoterapevtska skupina: Hemostatiki za lokalno zdravljenje, oznaka ATC: B02BC30
Pharmaco-therapeutic group: Vaccines, Bacterial and viral vaccines combined, ATC code: J07CA09
Farmakoterapevtska skupina: Cepiva, kombinacije bakterijskih in virusnih cepiv, oznaka ATC: J07CA09
Pharmaco-therapeutic group: Vaccines, Papillomavirus vaccines, ATC code: J07BM02 Mechanism of action
Farmakoterapevtska skupina: Cepiva, Cepiva proti virusom papiloma, oznaka ATC: J07BM02 Mehanizem delovanja
Pharmacodinamyc effect
Farmakodinamični učinki
Pharmacodynamic action
Farmakodinamično delovanje
pharmacodynamic activity of clopidogrel was not significantly influenced by the co-administration of phenobarbital, cimetidine, or oestrogen.
Poleg tega na farmakodinamično aktivnost klopidogrela ni pomembno vplivala sočasna uporaba fenobarbitala, cimetidina ali estrogena.
Pharmacodynamic activity was assessed through serial measurements of asparagine in serum (n=57) and cerebrospinal fluid (CSF) (n=50).
Farmakodinamično aktivnost so ocenili z zaporednimi meritvami asparagina v serumu (n=57) in likvorju (n=50).
Pharmacodynamic Drug-Drug Interactions (DDI)
Farmakodinamične interakcije med zdravili
Pharmacodynamic effects
Farmakodinamični učinki‌
Pharmacodynamic effects
Kontraindikacije
Pharmacodynamic Endpoint
Farmakodinamična primerjava
Pharmacodynamic investigations of copper metabolism in patients with Wilson’s disease included determinations of net copper balance and radiolabelled copper uptake.
Farmakodinamične raziskave presnove bakra pri bolnikih z Wilsonovo boleznijo so obsegale tudi določanje neto ravnovesja bakra in privzema radioaktivno označenega bakra.
Pharmacodynamic properties
265 (1,60)
Pharmacodynamic properties
Farmakodinamicne lastnosti
Pharmacodynamic properties
Farmakodinmične lastnosti
Pharmacodynamic properties
Predklinični podatki o varnosti
Pharmacodynamic properties
Za peroralno uporabo.
Pharmacodynamic studies were conducted in Wilson’s disease patients on the combination of Wilzin (50 mg three times daily) with ascorbic acid (1 g once daily), penicillamine (250 mg four times daily), and trientine (250 mg four times daily).
Pri bolnikih z Wilsonovo boleznijo so opravili farmakodinamične študije kombinacije Wilzina (50 mg trikrat na dan) z askorbinsko kislino (1 g enkrat na dan), penicilamina (250 mg štirikrat na dan), in trientina (250 mg štirikrat na dan).
pharmacoenhancement by means of
ki zahtevajo farmakokinetično
pharmacoenhancement since dosing
okrepitev, ker odmerjanja pri
Pharmacokine tic prope rties
Farmakokine tične lastnosti
Pharmacokinetic (PK) parameters were calculated from plasma factor X:C (one-stage clotting assay) activity measurements after subtraction of the pre-dose value.
Farmakokinetične (PK) parametre so izračunali iz meritev aktivnosti faktorja X:C (enostopenjski koagulacijski preskus) v plazmi po odštetju vrednosti pred odmerkom.
Pharmacokinetic / Pharmacodynamic relationships
Farmakokinetično/farmakodinamično razmerje
Pharmacokinetic / Pharmacodynamic relationships
Razmerje farmakokinetika/farmakodinamika
Pharmacokinetic analysis in one study was performed on nineteen of the patients, with a median (range) indinavir AUC 0-12hr, Cmax, and Cmin of 25,421 nM*h (21,489 – 36,236 nM*h), 5,758 nM (5,056 – 6,742 nM) and 239 (169 – 421 nM), respectively.
Analizo farmakokinetike v eni študiji so opravili pri 19-ih bolnikih, pri katerih je bila mediana (razpon) AUC0–12 h indinavirja 25421 nM*h (21489–36236 nM*h), Cmax 5758 nM (5056–6742 nM) in Cmin 239 (169–421 nM).
Pharmacokinetic analysis of patients in the VIEW2 study, of which 40% had renal impairment (24% mild, 15% moderate, and 1% severe), revealed no differences with respect to plasma concentrations of active drug after intravitreal administration every 4 or 8 weeks.
Farmakokinetične analize bolnikov v študiji VIEW2, v kateri je imelo 40 % bolnikov ledvično okvaro (24 % blago, 15 % zmerno in 1 % hudo), po intravitrealni aplikaciji vsake 4 ali vsakih 8 tednov, niso pokazale razlik v koncentracijah zdravilne učinkovine v plazmi.
Pharmacokinetic analysis revealed that adefovir exposure was comparable among 3 age groups, 2 to 6 years (0.3 mg/kg), 7 to 11 years (0.25 mg/kg) and 12 to 17 years (10 mg) and all age groups achieved adefovir exposure in the target range (for efficacy results see section 5.1), which was based on adefovir plasma concentrations in adult patients with chronic hepatitis B with established safety and efficacy profiles.
Farmakokinetična analiza je pokazala, da je bila koncentracija adefovirja primerljiva med tremi starostnimi skupinami, in sicer 2 do 6 let (0,3 mg/kg), 7 do 11 let (0,25 mg/kg) in 12 do 17 let (10 mg), ter da so vse starostne skupine dosegle koncentracijo adefovirja v ciljnem obsegu (za rezultate učinkovitosti glejte poglavje 5.1), ki je temeljil na plazemskih koncentracijah adefovirja pri odraslih bolnikih s kroničnim hepatitisom B z znanim profilom varnosti in učinkovitosti.
Pharmacokinetic behaviour of CellCept in the elderly ( 65 years) has not been formally evaluated.
Farmakokinetičnih parametrov zdravila CellCept pri starejših bolnikih (starih 65 let ali več) niso proučevali.
Pharmacokinetic behaviour of mycophenolate mofetil in the elderly (°65 years) has not been formally evaluated.
Farmakokinetičnih parametrov mofetilmikofenolata pri starejših bolnikih (starih 65 let ali več) niso proučevali.
pharmacokinetic change.
premembe farmakokinetike.
pharmacokinetic data
farmakokinetičnimi podatki
Pharmacokinetic data after oral administration of nalmefene to patients with severe hepatic impairment are not available (see sections 4.3 and 4.4).
Farmakokinetični podatki po peroralnem vnosu nalmefena pri bolnikih s hudo okvaro jeter niso na voljo (glejte poglavja 4.3 in 4.4.).
Pharmacokinetic data are not available for STAYVEER in young children with this disease.
Farmakokinetični podatki za zdravilo STAYVEER pri majhnih otrocih s to boleznijo niso na voljo.
Pharmacokinetic data are not available for Tracleer in young children with this disease.
Farmakokinetični podatki za zdravilo Tracleer pri majhnih otrocih s to boleznijo niso na voljo.
Pharmacokinetic data are not available in the elderly (over 65 years of age).
Farmakokinetični podatki zdravila pri starostnikih (starih nad 65 let), niso na razpolago.
Pharmacokinetic data demonstrated that the teduglutide exposure of fetal rabbits and suckling rat pups was very low.
Farmakokinetični podatki so pokazali, da je bila izpostavljenost teduglutidu pri zajčjih zarodkih in podganjih dojenih mladičih zelo majhna.
Pharmacokinetic data for healthy volunteers pooled across Phase 1 studies (using the 100 mg single oral dose) and analyzed for potential differences based on sex, age, race, and BMI demonstrated no significant differences.
Farmakokinetični podatki o zdravih prostovoljcih, združeni iz študij faze 1 (z uporabo posameznega peroralnega odmerka 100 mg) ter analizirani glede morebitnih razlik glede na spol, starost, raso in ITM, niso pokazali pomembnih razlik.
Pharmacokinetic data from patients with hepatocellular carcinoma having mild to moderate hepatic impairment indicate that AsIII or AsV do not accumulate following twice-weekly infusions.
Farmakokinetični podatki bolnikov s hepatoceličnim karcinomom z blago do zmerno okvaro delovanja jeter kažejo, da se AsIII ali AsV ne nalagata po indunfiranju dvakrat na teden.
Pharmacokinetic data from studies BO15935 and M77004 in women with HER2-positive MBC suggested that exposure to paclitaxel and doxorubicin (and their major metabolites 6-α hydroxyl- paclitaxel, POH, and doxorubicinol, DOL) was not altered in the presence of trastuzumab (8 mg/kg or 4 mg/kg IV loading dose followed by 6 mg/kg q3w or 2 mg/kg q1w IV, respectively).
Farmakokinetični podatki iz študij BO15935 in M77004 pri bolnicah s HER2-pozitivnim metastatskim rakom dojk so nakazali, da izpostavljenost paklitakselu in doksorubicinu (in njunima glavnima metabolitoma 6-α hidroksil-paklitakselu, POH, in doksorubicinolu, DOL) ni bila spremenjena v prisotnosti trastuzumaba (uvajalni odmerek 8 mg/kg, ki mu je sledil odmerek 6 mg/kg iv. vsake tri tedne ali uvajalni odmerek 4 mg/kg iv., ki mu je sledil odmerek 2 mg/kg iv. enkrat na teden).
Pharmacokinetic data has been obtained for dolutegravir, abacavir and lamivudine separately.
Farmakokinetični podatki so bili pridobljeni za dolutegravir, abakavir in lamivudin posamezno.
Pharmacokinetic data have been obtained for dolutegravir, lamivudine and abacavir separately.
Farmakokinetični podatki so bili pridobljeni za dolutegravir, lamivudin in abakavir posamezno.
Pharmacokinetic data have been obtained for lamivudine and abacavir alone.
Farmakokinetični podatki so bili pridobljeni za abakavir in lamivudin posamezno.
Pharmacokinetic data in children < 4 years are lacking, but clinical experience is available from 8 months of age, and when started at the recommended daily dose of 1-2 mg/kg, no safety concerns have been identified.
Podatki o farmakokinetiki pri otrocih do 4 let manjkajo, vendar so na voljo klinične izkušnje od starosti 8 mesecev dalje in ob začetku zdravljenja s priporočenim dnevnim odmerkom 1–2 mg/kg ni bilo pomislekov glede varnosti.
Pharmacokinetic data in patients with severe renal impairment (CLcr 15 to 29 mL/min) are limited (n = 1), therefore no dosage recommendations can be made.
Farmakokinetičnih podatkov pri bolnikih s hudo ledvično okvaro (CLcr od 15 do 29 ml/min) je malo (n = 1), zato ni mogoče dati priporočil za odmerjanje.
Pharmacokinetic data indicated that no dose adjustment is necessary for elderly patients (see section 5.2).
Farmakokinetični podatki kažejo, da prilagoditev odmerka za starejše bolnike ni potrebna (glej poglavje 5.2).
Pharmacokinetic data on 33 patients (age range 0.77 – 13.7 years) in the intensive sampling group demonstrated that clearance of nevirapine increased with increasing age in a manner consistent with increasing body surface area.
Farmakokinetični podatki o 33 bolnikih (starostni razpon 0,77 - 13,7 leta) v intenzivni vzorčni skupini so pokazali, da se očistek nevirapina veča s starostjo, skladno s povečevanjem telesne površine.
Pharmacokinetic data on 33 patients (age range 0.77 – 13.7 years) in the intensive sampling group demonstrated that clearance of nevirapine increased with increasing age in a manner consistent with increasing body surface area.
Farmakokinetični podatki o 33 bolnikih (starostni razpon 0,77-13,7 leta) v intenzivni vzorčni skupini so pokazali, da se očistek nevirapina veča s starostjo, skladno s povečevanjem telesne površine.
Pharmacokinetic data reveal no relevant differences due to gender in the exposure to riociguat.
Farmakokinetični podatki niso pokazali razlik v izpostavljenosti riociguatu glede na spol.
Pharmacokinetic data reveal no relevant differences due to weight in the exposure to riociguat.
Farmakokinetični podatki niso pokazali razlik v izpostavljenosti riociguatu glede na telesno maso.
Pharmacokinetic data reveal no relevant inter-ethnic differences.
Farmakokinetični podatki niso pokazali pomembnih razlik glede na etično pripadnost.
Pharmacokinetic data were available from 215 patients with refractory CLL.
Farmakokinetični podatki so bili na voljo za 215 bolnikov z neodzivno KLL.
Pharmacokinetic data were obtained in healthy volunteers, in renal transplant patients and in multiple sclerosis patients.
Farmakokinetične podatke so pridobivali pri zdravih prostovoljcih, pri bolnikih po presaditvi ledvic in pri bolnikih z multiplo sklerozo.
Pharmacokinetic data were obtained in paediatric patients with type 3 Gaucher disease aged 3 to 15 years, and patients with Niemann-Pick type C disease aged 5–16 years.
Farmakokinetični podatki so bili pridobljeni pri pediatričnih bolnikih z Gaucherjevo boleznijo tipa 3, starih 3 do 15 let, in pri bolnikih z Niemann-Pickovo boleznijo tipa C, starih 5–16 let.
Pharmacokinetic differences due to race have been studied in 1091 postmenopausal women, including 93.1% White, 3.9% Black, 1.8% Asian and 1.1% other in VVA trials.
Farmakokinetične razlike zaradi rase so preučili pri 1.091 ženskah po menopavzi, vključno s 93,1% belk, 3,9% črnk, 1,8% Azijk in 1,1% pripadnic drugih ras v preskušanjih VVA.
Pharmacokinetic drug interaction studies with Efficib have not been performed; however, such studies have been conducted with the individual active substances, sitagliptin and metformin.
Študije farmakokinetičnih interakcij z zdravilom Efficib niso bile izvedene, vendar pa so take študije opravili s posameznima zdravilnima učinkovinama, sitagliptinom in metforminom.
Pharmacokinetic drug interaction studies with Janumet have not been performed; however, such studies have been conducted with the individual active substances, sitagliptin and metformin.
Študije farmakokinetičnih interakcij z zdravilom Janumet niso bile izvedene, vendar pa so take študije opravili s posameznima zdravilnima učinkovinama, sitagliptinom in metforminom.
Pharmacokinetic drug interaction studies with Jentadueto have not been performed; however, such studies have been conducted with the individual active substances, i.e. linagliptin and metformin.
Študij o farmakokinetičnih interakcijah z zdravilom Jentadueto niso izvedli, opravili pa so jih z njegovima posamičnima zdravilnima učinkovinama, linagliptinom in metforminom.